A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects
Phase of Trial: Phase I/II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs SYN 023 (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Pharmacodynamics
- Acronyms RabiesMab
- Sponsors Synermore Biologics
- 14 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
- 14 Aug 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Oct 2017.
- 10 Nov 2016 New trial record